Patents by Inventor Erasmus Huber

Erasmus Huber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190324024
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Klaus Hirzel, Caroline Dorothea Hojer, Erasmus Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Leopold Von Proff
  • Patent number: 7906629
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: March 15, 2011
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Erasmus Huber, Herbert W. Von Der Eltz
  • Patent number: 7649085
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: January 19, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Richard Terry Root, Erasmus Huber, Herbert W. Von Der Eltz
  • Patent number: 7569678
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: August 4, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Erasmus Huber, Herbert W. Von Der Eltz, Sigrun Metz, Peter Kern
  • Patent number: 7482437
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 27, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Richard Terry Root, Mitali Ghoshal, Erasmus Huber, Herbert W. Von Der Eltz, Sigrun Metz, Peter Kern
  • Patent number: 7332354
    Abstract: The present invention relates to a chemical compound comprising a light emitting moiety precursor and a precursor of a leaving group, bound to each other by an amide or by an ester bond and characterized in that the leaving group precursor upon oxidation is converted into the leaving group. The invention also relates to compounds additionally comprising a coupling group to the use of such compounds for labeling of biomolecules and more generally to the use of such compounds in chemiluminescence detection procedures.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: February 19, 2008
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Rupert Herrmann, Hans-Peter Josel, Erasmus Huber, Ursula Klause
  • Publication number: 20080021201
    Abstract: Activated haptens useful for generating immunogen to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Application
    Filed: February 1, 2007
    Publication date: January 24, 2008
    Inventors: Gerald Sigler, Raymond Hui, Ina Deras, Erasmus Huber, Herbert Von Der Eltz, Sigrun Metz, Peter Kern
  • Publication number: 20070155959
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Application
    Filed: January 31, 2007
    Publication date: July 5, 2007
    Inventors: Gerald Sigler, Raymond Hui, Ina Deras, Richard Root, Mitali Ghoshal, Erasmus Huber, Herbert Von Der Eltz, Sigrun Metz, Peter Kern
  • Publication number: 20070149565
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Application
    Filed: January 26, 2007
    Publication date: June 28, 2007
    Inventors: Gerald Sigler, Raymond Hui, Ina Deras, Richard Root, Mitali Ghoshal, Erasmus Huber, Herbert Von Der Eltz, Sigrun Metz, Peter Kern
  • Publication number: 20070148708
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavor. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Application
    Filed: January 31, 2007
    Publication date: June 28, 2007
    Inventors: Gerald Sigler, Raymond Hui, Ina Deras, Richard Root, Mitali Ghoshal, Erasmus Huber, Herbert Von Der Eltz, Sigrun Metz, Peter Kern
  • Publication number: 20070142631
    Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.
    Type: Application
    Filed: February 9, 2007
    Publication date: June 21, 2007
    Inventors: Mitali Ghoshal, Gerald Sigler, Raymond Hui, Ronald Hawley, Eva Hoess, Erasmus Huber, John Patterson, Salvatore Salamone, Allan Dorn
  • Publication number: 20070141643
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Application
    Filed: February 2, 2007
    Publication date: June 21, 2007
    Inventors: Gerald Sigler, Raymond Hui, Ina Deras, Richard Root, Mitali Ghoshal, Erasmus Huber, Herbert Von Der Eltz, Sigrun Metz, Peter Kern
  • Patent number: 7193065
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for HIV protease inhibitors. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group common to all HIV protease inhibitors, e.g., saquinavir, nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, and atazanavir.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: March 20, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Richard Terry Root, Mitali Ghoshal, Erasmus Huber, Herbert W. Von Der Eltz, Sigrun Metz, Peter Kern
  • Publication number: 20060264618
    Abstract: Monoclonal antibodies specific for lopinavir having less than 10% cross-reactivity with saquinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies are described.
    Type: Application
    Filed: May 26, 2006
    Publication date: November 23, 2006
    Inventors: Ina Deras, Gerald Sigler, Raymond Hui, Richard Root, Mitali Ghoshal, Erasmus Huber, Herbert Von Der Eltz, Sigrun Metz, Peter Kern
  • Publication number: 20060211107
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.
    Type: Application
    Filed: May 26, 2006
    Publication date: September 21, 2006
    Inventors: Gerald Sigler, Raymond Hui, Ina Deras, Richard Root, Erasmus Huber, Herbert Von Der Eltz
  • Publication number: 20050009076
    Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.
    Type: Application
    Filed: July 27, 2004
    Publication date: January 13, 2005
    Inventors: Mitali Ghoshal, Gerald Sigler, Raymond Hui, Ronald Hawley, Eva Hoess, Erasmus Huber, John Patterson, Salvatore Salamone, Allan Dorn
  • Publication number: 20040248225
    Abstract: The present invention relates to substituted hydrazides of a luciferin dye or to substituted hydrazides of a dye analogous thereto. These chemical compounds comprise the luciferin dye or the dye analogue thereto as a light emitting moiety precursor and the substituted hydrazide as a leaving group precursor, wherein a nitrogen atom of said hydrazide group is bound to a carbonyl group or to a group chemically equivalent to said carbonyl group of said luciferin or said analogue. The invention also relates to conjugates between a biomolecule and these compounds and to the use of such compounds in chemiluminescence procedures.
    Type: Application
    Filed: June 25, 2004
    Publication date: December 9, 2004
    Inventors: Dieter Heindl, Rupert Herrmann, Hans-Peter Josel, Erasmus Huber, Ursula Klause, Oliver Simon
  • Patent number: 6821744
    Abstract: A method for quantifying an HIV protease inhibitor in a sample includes combining HIV protease, a conjugate comprising an HIV protease inhibitor analog, and a sample suspected of containing an HIV protease inhibitor. The HIV protease and the conjugate are capable of forming a detectable complex. The method also includes measuring the amount of the detectable complex, and relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the sample.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: November 23, 2004
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert von der Eltz, Lili Arabshahi, Haijuan Li, Erasmus Huber
  • Publication number: 20040214999
    Abstract: The present invention relates to a chemical compound comprising a light emitting moiety precursor and a precursor of a leaving group, bound to each other by an amide or by an ester bond and characterized in that the leaving group precursor upon oxidation is converted into the leaving group. The invention also relates to compounds additionally comprising a coupling group to the use of such compounds for labeling of biomolecules and more generally to the use of such compounds in chemiluminescence detection procedures.
    Type: Application
    Filed: June 14, 2004
    Publication date: October 28, 2004
    Inventors: Dieter Heindl, Rupert Herrmann, Hans-Peter Josel, Erasmus Huber, Ursula Klause
  • Publication number: 20040127689
    Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for HIV protease inhibitors. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group common to all HIV protease inhibitors, e.g., saquinavir, nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, and atazanavir.
    Type: Application
    Filed: September 24, 2003
    Publication date: July 1, 2004
    Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Richard Terry Root, Mitali Ghoshal, Erasmus Huber, Herbert W. Von Der Eltz, Sigrun Metz, Peter Kern